Opko Health Inc. - OPK STOCK NEWS

OPKO Health, Inc. (NASDAQ: OPK) has completed enrollment for the Phase 2 trial of RAYALDEE® for treating mild-to-moderate COVID-19, exceeding the expected total with 171 participants. The randomized study will assess RAYALDEE's efficacy in raising serum 25-hydroxyvitamin D levels and the resolution time of COVID-19 symptoms. Primary endpoints include achieving the targeted vitamin D levels, while secondary endpoints focus on hospitalization rates and overall illness severity. Topline results are anticipated later this year.

OPKO Health, Inc. (NASDAQ: OPK) has announced participation in two significant virtual investor conferences in September 2021. The 14th Annual Barrington Research Fall Conference will take place on September 9, 2021, featuring one-on-one and small-group meetings with management. Subsequently, OPKO will attend the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, where management will engage in a fireside chat and additional investor meetings. A recording of the fireside chat will be available on OPKO's website starting September 13.

Rite Aid (NYSE: RAD) and BioReference, an OPKO Health company (NASDAQ: OPK), will provide free COVID-19 testing for New York State public school students ahead of the 2021-2022 school year. This ‘Back to School’ program allows students aged 4-17 to access RT-PCR tests at 115 Rite Aid drive-thru locations. Testing is voluntary, with results delivered digitally to parents. Governor Kathy Hochul emphasized the program's importance in combating the Delta variant and ensuring safe school environments. The initiative aligns with federal efforts to expand school testing.

BioReference Laboratories, part of OPKO Health (NASDAQ:OPK), has acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche. This acquisition enhances BioReference's non-invasive prenatal screening (NIPS) capabilities, particularly through the Harmony Prenatal Test, which is widely used and has been performed on over 1.5 million patients. The transaction aligns with BioReference's 40-year commitment to women's health and aims to improve prenatal testing accessibility, impacting millions of pregnancies annually.

OPKO Health reports business highlights and financial results for Q2 2021. BioReference Laboratories test volume increased 32% compared to Q2 2020. BRL processed 2.8 million COVID-19 PCR tests and has capacity for over 100,000 tests per day. BRL performed 132,000 COVID-19 serology tests. OPKO entered into agreements with Nicoya Therapeutics and CAMP4 Therapeutics. OPKO sold a facility in Ireland for $65 million. Diagnostics revenue increased to $397.2 million. Pharmaceuticals revenue was $35.7 million. Consolidated total revenues were $442.4 million. Net loss for Q2 2021 was $16.2 million.

OPKO Health, Inc. (NASDAQ: OPK) will report its Q2 2021 operating and financial results on July 29, 2021, after U.S. market close. The company will provide a detailed business update during a conference call at 4:30 PM ET on the same day. Interested parties can pre-register for the call or access it via the provided webcast link. OPKO focuses on biopharmaceuticals and diagnostics, aiming to lead in rapidly growing markets through innovative technologies. Additional details and a replay will be available on OPKO's website.

OPKO Health, Inc. (NASDAQ: OPK) has entered into a worldwide agreement with CAMP4 Therapeutics for developing therapeutics based on the AntagoNAT technology. This agreement marks a significant step in advancing OPKO's lead compound for Dravet syndrome into clinical trials. OPKO will receive an upfront payment and is eligible for up to $93.5 million in milestone payments, plus royalties on product sales. The collaboration not only enhances OPKO’s focus on drug development but also validates its proprietary technology.

OPKO Health, Inc. (NASDAQ: OPK) will participate in the virtual Ladenburg Thalmann Healthcare Conference on July 13-14, 2021. Management will engage in a fireside chat on July 13 at 8:30 a.m. Eastern Time and will conduct one-on-one virtual meetings with investors throughout the day. The fireside chat will be archived in OPKO Health's Investors section on their website for future viewing. OPKO is focused on establishing a strong market position in biopharmaceuticals and diagnostics, leveraging its innovative technologies.

OPKO Health, Inc. (NASDAQ: OPK) has appointed Katherine Stueland as President and CEO of its subsidiary, GeneDx, Inc. Stueland, previously a Chief Commercial Officer at Invitae Corporation, brings two decades of leadership in the healthcare industry. Under her guidance, GeneDx aims to leverage genomic information to enhance patient care, emphasizing access to diagnostics for rare genetic disorders. The company has been a leading player in genomics for over 20 years, offering a wide array of genetic testing services.